First-line RCC immunotherapy combinations shine at ASCO GU

Competition in first-line renal cell carcinoma remains tight as new checkpoint combinations read out in Phase III. With two years of progression free survival, the latest combination to join the bunch — Keytruda plus Lenvima — may be the most effective.

In an abstract released ahead of the American Society of Clinical Oncology Genitourinary Cancers Symposium, Merck & Co. Inc. (NYSE:MRK) reported a 24-month median PFS and a 71% ORR for the combination of PD-1 inhibitor Keytruda pembrolizumb plus VEGFR inhibitor Lenvima lenvatinib from Eisai Co. Ltd. (Tokyo:4523). ...